If standardized and longitudinally validated (e.g., particle counts, length distributions, and nanomechanical signatures), such AFM-based metrics could complement conventional Aβ/tau/α-Syn measures for risk stratification and pharmacodynamic monitoring, including in DLB. Here, MAPT is linked to Lewy body dementia.